Invest Ophthalmol Vis Sci by MERLE, Bénédicte M. J. et al.
Retina
Genetic Susceptibility, Diet Quality, and Two-Step
Progression in Drusen Size
Bénédicte M. J. Merle,1 Bernard Rosner,2 and Johanna M. Seddon3
1University of Bordeaux, Inserm, Bordeaux Population Health Research Center, team LEHA, UMR 1219, Bordeaux, France
2Channing Division of Network Medicine, Harvard Medical School, Harvard University, Boston, Massachusetts, United States
3Department of Ophthalmology and Visual Sciences, University of Massachusetts Medical School, Worcester, Massachusetts,
United States
Correspondence: Johanna M.
Seddon, University of Massachusetts
Medical School, 55 Lake Avenue
North, S3-119, Worcester 01655, MA,
USA;
johanna_seddon@yahoo.com.
Received: November 27, 2019
Accepted: February 27, 2020
Published: May 14, 2020
Citation: Merle BMJ, Rosner B,
Seddon JM. Genetic susceptibility,
diet quality, and two-step
progression in drusen size. Invest
Ophthalmol Vis Sci. 2020;61(5):17.
https://doi.org/10.1167/iovs.61.5.17
PURPOSE. To investigate the relationship of growth in drusen size with genetic suscepti-
bility and adherence to the alternate Mediterranean diet.
METHODS. Participants in this analysis had complete ocular, genetic, and dietary data
with mean follow-up time of 10.2 years in the Age-Related Eye Disease database. Maxi-
mal drusen size was graded on an ordinal scale and two-step progression was deter-
mined. A genetic risk score using variants associated with advanced AMD and derived
from a stepwise regression model yielded 11 variants in 8 genes. Adherence to the alter-
nate Mediterranean diet was assessed using a nine-component score based on intake of
vegetables, fruits, legumes, whole cereals, fish, meat, nuts, alcohol, and monounsaturated-
to-saturated fatty acids ratio. Multivariate Cox proportional hazards models were used.
RESULTS. Among 3023 eligible eyes, 19% had drusen growth. In the stepwise selection,
common and rare risk alleles for CFH Y402H, CFH rs1410996, CFH R1210C, C3 R102G,
C3 K155Q, and ARMS2/HTRA1, as well as VEGF-A, TIMP3, NPLOC4, and HSPH1 variants
were significantly associated with 2-step progression in drusen size, and the C2 E318D
protective allele conferred decreased risk, adjusting for other covariates. A higher genetic
risk score conferred a higher risk (hazard ratio per 1-unit increase, 2.68; 95% confidence
interval, 2.23–3.23; P < 0.001), and a medium/high adherence to alternate Mediterranean
diet score (4–9) tended to lower risk (hazard ratio, 0.83; 95% confidence interval, 0.68–
0.99; P = 0.049), adjusting for all covariates.
CONCLUSIONS. Genetic susceptibility was independently related to drusen growth. A
Mediterranean-style diet with healthful nutrient-rich foods (fruits, vegetables, legumes
and fish), may reduce enlargement of drusen, the hallmark of AMD.
Keywords: mediterranean diet, drusen progression, genetics, nutrition, AMD
AMD is the leading cause of visual impairment amongthe elderly population in industrialized countries.1
Advanced forms of AMD lead to central vision loss. Early
AMD and intermediate forms, asymptomatic or associated
with minimal vision loss, affect between 15% and 25% of the
population aged 75 to 85 years.2 These early stages are char-
acterized by the presence of drusen and pigment alterations
in the macular region, which usually precede geographic
atrophy and neovascular disease, the two advanced subtypes
causing visual loss. Drusen—yellow deposits between the
retinal pigment epithelium and Bruch’s membrane—are the
major hallmarks of AMD and are heterogeneous with regard
to shape, size, location, and extent.3–6
Many studies have investigated factors associated with
progression from nonadvanced to advanced AMD. This
transition is multifactorial7 and is influenced by demo-
graphic, behavioral, environmental, phenotypic, and genetic
factors, including age, smoking,8–10 and nutrition,11–14 as
well as several genetic variants.7,15–18 However, informa-
tion is sparse related to factors associated with drusen size
progression, even though early AMD with drusen increases
the risk of developing more advanced disease.9,19,20
Further exploration of increasing drusen size over time
and how such progression is influenced by genetic and
modifiable factors would be helpful to identify higher risk
subtypes among the millions of people world-wide diag-
nosed with nonadvanced stages of AMD. This knowledge
could also increase understanding of the biology of drusen
growth and could lead to preventive measures before the
development of visually disabling forms of AMD. In this
study, we assessed the association of drusen size progres-
sion measured on an ordinal scale with common and rare
AMD genetic variants and diet quality.
METHODS
Study Population
Data were derived from the Age-Related Eye Disease Study
(AREDS) database. The original study was a multicenter,
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FIGURE 1. Flowchart showing study sample selection.
randomized clinical trial to assess the effect of antioxi-
dant and mineral supplements on the risk of AMD and
cataracts.21 The four treatment groups were antioxidants,
zinc, antioxidants and zinc combined, or placebo. The proto-
col was approved by a data and safety monitoring committee
and by each institutional review board for the participating
ophthalmic centers. Participants were aged 55 to 80 years
at baseline and were required to have at least one eye with
a visual acuity of no worse than 20/32. Examinations were
performed at baseline, at the 2-year visit, and annually there-
after during 13 years of follow-up. The mean follow-up time
was 10.2 years. Informed consent was obtained from partici-
pants before enrollment, and all research followed the tenets
of the Declaration of Helsinki.
Procedures
Data on demographic factors, environmental exposures, and
habitual diet were obtained. Retinal photographs were taken
according to a standardized protocol by certified photog-
raphers using certified cameras.22 Trained fundus graders,
masked to clinical and phenotypic information, ascertained
signs of AMD from annual stereoscopic color images using
a standardized protocol at a single reading center.
Study Participants
Data were accessed from NIH Database of Genotypes and
Phenotypes. Figure 1 illustrates the selection procedures for
participants included in the present study. Among the 4757
participants at baseline, 618 participants consented only to
“eye research” and, for these participants, phenotype and
genetic data could not be linked and they were not included
in the analyses. Among the remaining 4139 participants who
consented to “general research,” we excluded 995 partici-
pants for lack of a genetic specimen. Of the 3144 partici-
pants with a genetic specimen, 4 were removed from the
dataset owing to lack of follow-up information. Thirty-nine
participants with advanced AMD in both eyes at baseline and
898 participants with the highest drusen sizes (drusen grade
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3 or 4, as defined below) or missing drusen data in both
eyes at baseline were also removed. Furthermore, an addi-
tional 365 participants were excluded from the dataset: 273
because of incomplete genotyping information (genotyping
rate of <100% for the variants evaluated), and 92 because
of an invalid total energy intake (valid total energy intake
range is 600–3200 kcal for women and 600–4200 kcal for
men). Complete data, including AMD grade at baseline and
at least one follow-up visit, dietary data, and demographic,
behavioral, and genetic covariates were available for 1838
participants and 3023 eyes at risk for drusen progression.
Most of our sample (96%) was Caucasian.
Definition of Drusen Size Progression
Advanced AMD was defined by neovascular AMD, central
or noncentral geographic atrophy, or both advanced forms
together. Drusen grades based on measured maximum size
within the grid among eyes without advanced AMD were
defined as follows: 0, no drusen or questionable drusen;
1, small drusen (<63 μm); 2, intermediate drusen (63–
124 μm); 3, large drusen (125–249 μm); and 4, very large
drusen (≥250 μm). Eye-specific progression of maximum
drusen size according to this ordinal scale was defined as an
eye advancing at least two grades during the study period.
Follow-up for this analysis ended when an eye progressed
two grades over the study period (progression from grade 0
to grade 2, or from grade 1 to grade 3, or from grade 2 to
grade 4). Eyes that had no indication of drusen size progres-
sion were censored if and when they reached advanced AMD
or at the last follow-up visit. Eyes with advanced AMD or
highest drusen sizes (drusen grade 3 or 4) at baseline, and
therefore unable to progress 2 grades, were excluded from
the analysis.
Dietary Data
Data on food consumption were collected at enrollment
with a validated, self-administered, semiquantitative 90-item,
food frequency questionnaire based on the National Cancer
Institute Health Habits and History Questionnaire (version
2.1). Participants were asked to report how often, on aver-
age, they consumed each food or beverage item during the
past year. Consumption was classified into nine levels from
“never or less than one per month” to “six or more per day.”
For each item, average serving size was recorded as “small,”
“medium, or “large” with respect to standard examples.
The University of Minnesota Nutrition Coordinating Center
Food Composition Database (version 31) was used with
the estimated quantity of nutrient intake and DietSys soft-
ware (version 3.0; Block Dietary Data Systems, Berkeley, CA)
to derive individual nutrient values for each questionnaire
item. The instrument was validated through a telephone-
administered 24-hour dietary recall at 3 and 6 months after
enrollment in a sample of 197 randomly selected partici-
pants.
We used these raw diet data to create an alternate
Mediterranean Diet (aMeDi) score, which is a validated score
widely used to estimate adherence to the Mediterranean
diet in the US population.23 We previously determined that
this score was related to progression from nonadvanced to
advanced AMD,13 and this finding was later confirmed in
a European population.14 This score is a slightly modified
version of the original Mediterranean Diet score published
by Trichopoulou et al.24 and is more representative of the
dietary patterns observed in the US population. The origi-
nal Mediterranean diet does not distinguish between whole
and refined grains and includes dairy products rather than
nuts. The aMeDi score includes nine components: vegeta-
bles (excluding potatoes), fruits, legumes, whole grain, nuts,
fish, red and processed meat, alcohol consumption, and
the monounsaturated fatty acid to saturated fatty acid ratio.
Daily intake of each food or beverage group was calculated
as the sum of the number of medium servings consumed
per day. For each component hypothesized to benefit health,
one point was given if intake was above the sex-specific
median, and zero otherwise. For alcohol, one point was
given to men if their consumption was between 2.7 and 12.2
g/d and women if their consumption was between 1.0 and
4.2 g/d. These cutoffs, corresponding to the third quartile of
distribution of total alcohol consumption in this population,
were chosen to represent mild to moderate consumption.
For components presumed to be detrimental to health, one
point was given if intake was below the sex-specific median,
and zero otherwise. Total aMeDi score was calculated by
adding the scores (zero or one point) for each food category
for each participant. Scores range from zero (nonadherence)
to nine (perfect adherence).
Demographic and Behavioral Covariates
Baseline age, sex, education, smoking, body mass index
(BMI; kg/m2), AREDS treatment group, multivitamin supple-
ment use, and ocular characteristics were included. Pack-
years was defined as the product of smoking duration (years)
by average packs of cigarettes smoked per day. The median
value among ever smokers was 20 pack-years, and smoking
status was classified as follows: never, less than 20 pack-
years, and 20 pack-years or more. AREDS treatment was
defined as antioxidant alone, zinc alone, antioxidant plus
zinc group, or placebo. Multivitamin use was defined as
never for participants who reported never having taken a
multivitamin supplement and who were not taking Centrum
during the study, and was defined as ever for participants
who declared that they had taken a multivitamin supplement
in the past or at present, or were taking Centrum during the
study.
Genotype Data
DNA samples were purchased and we assessed genetic vari-
ants associated with advanced AMD using array-based and
gene sequencing platforms, as previously described.17,25–27
All single nucleotide polymorphisms had a high geno-
type call rate (>98%). Variants in this study represented
common and rare variants in all known genetic path-
ways: complement factor H (CFH) Y402H (rs1061170);
CFH rs1410996; CFH R1210C (rs121913059); CFH N1050Y
(rs35274867); complement factor I (CFI) (rs10033900);
complement factor B (CFB) R32Q (rs641154); complement
component 2 (C2) E318D (rs9332739); complement compo-
nent 3 (C3) R102G (rs2230199); C3 K155Q (rs147859257);
complement component 9 (C9) (rs34882957); vascu-
lar endothelial growth factor A (VEGFA) (rs943080);
transforming growth factor, beta receptor I (TGFBR1)
(rs334353); hepatic lipase (LIPC) (rs10468017); cholesteryl
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ester transfer protein (CETP) (rs3764261); ATP binding
cassette subfamily A member 1 (ABCA1) (rs1883025);
apolipoprotein C1 (APOC1) (rs4420638); apolipoprotein H
(APOH) (rs1801689); age-related maculopathy susceptibil-
ity 2 (ARMS2/HTRA1) (rs10490924); Pellino E3 ubiquitin
protein ligase family member 3 (PELI3) (rs145732233);
TNF receptor superfamily member 10a (TNFRSF10A)
(rs3278062); solute carrier family 16 member 8 (SLC16A8)
(rs8135665); paired immunoglobin-like type 2 receptor
beta and alpha (PILRB/PILRA) (rs11769700); transmem-
brane protein 97 (TMEM97) (rs704); Collagen type VIII
alpha 1 chain (COL8A1) (rs13095226); collagen type IV
alpha 3 chain (COL4A3 (rs11884770); chymotrypsinogen
B1 (CTRB1) (rs8056814); A disintegrin-like and metallo-
protease with thrombospondin type 1 motif 9 (ADAMTS9)
(rs6795735); tissue inhibitor of metalloproteinases inhibitor
3 (TIMP3) (rs9621532); DNA repair protein RAD51 para-
log B (RAD51B) (rs8017304); nuclear protein localization
4 homolog/tetraspanin 10 (NPLOC4/TSPAN10) (rs9895741);
and heat shock protein family H (HSPH1/B3GALTL)
(rs9542236).
Statistical Analysis
The associations between baseline demographic, behavioral,
and ocular characteristics with drusen size progression were
determined using Cox proportional hazards models with the
eye as the unit of analysis, with estimation of hazard ratios
(HR) and 95% confidence intervals (CI). Comparisons were
adjusted for age and sex.
For analysis of progression of maximum drusen size, we
used survival analysis methodology with the eye as the unit
of analysis. The associations of each single nucleotide poly-
morphism with drusen size progression were analyzed using
Cox proportional hazards models (PROC PHREG with the
covariate aggregate option in SAS 9.4, SAS Institute Inc.,
Cary, NC), adjusting for correlation of drusen progression
in the 2 eyes. In the multivariate models we adjusted for
age (≤64, 65–to 74, and >74 years), sex, education (high
school or less, high school or more), smoking (never smoker,
<20, and ≥20 pack-years), BMI (<25.0, 25.0–29.9, and ≥30
kg/m2), AREDS treatment (four treatment categories), multi-
vitamin supplement use (never, ever), and maximum drusen
size category at baseline in each eye.
To select the genetic variants most highly related to
increase in drusen size, a stepwise regression method was
applied with a significance level with a P value of 0.05 or
less for entry and a P value of 0.10 or greater for remaining
in the model.17 Eight genetic variants were retained and a
composite genetic risk score was calculated using the sum
of the regression coefficients multiplied by the correspond-
ing number of risk alleles and summed over these genetic
variants, similar to previous analyses.17,28
Participants were classified according to categories of
the aMeDi score.13 The aMeDi score was categorized as
low (0–3) or medium-high (4–9). The association of aMeDi
score with drusen size progression was analyzed using the
methodology explained above and models were further
adjusted for total energy intake (kilocalories per day).
Interactions between the genetic risk score (classified as
below the median, greater than or equal to the median) and
aMeDi score were analyzed using the fully adjusted model
described above. P values of less than 0.05 were considered
statistically significant for all analyses. All statistical analyses
were performed using SAS software, version 9.4.
RESULTS
The incidence of drusen progression is shown in Supple-
mentary Figure S1. The mean follow-up time was 10.2 years
(range, 3–13 years), and 82.4% had 10 years or more of
follow-up time and 1.7% had 5 years or less. Among 3023
eyes, 8% had two-step drusen growth at 5 years, and 19%
had drusen growth at 10 years, based on the Kaplan-Meier
survival analysis. Baseline demographic, behavioral, and
ocular characteristics for eyes which were progressors or
nonprogressors, adjusted for age and sex, are shown in the
Supplementary Table S1. Older age, smoking, and drusen
size at baseline were associated with higher risk of drusen
progression (Ptrend < 0.0001, Ptrend = 0.049 and Ptrend <
0.0001, respectively). Sex, education, BMI, AREDS treatment,
and multivitamin use did not differ significantly between
progressing and nonprogressing eyes.
The associations between drusen growth and genetic
susceptibility are displayed in Table 1. The risk alleles for
CFH Y402H, CFH rs1410996, C3 R102G, ARMS2/HTRA1, and
HSPH1 rs9542236 variants were significantly associated with
an increased risk of drusen size progression, and the protec-
tive alleles for C2 E318D and ABCA1 conferred a signifi-
cant decreased risk of progression, after adjustment for age,
sex, education, smoking, BMI, drusen size grade at baseline,
AREDS treatment, and multivitamin supplement use.
After further adjustments for all genes together in the
same model (Table 1, model 2), higher risk of two-step
drusen enlargement was associated with common and rare
variants in CFH: rs1410996 and CFH R1210C, and variants
in C3, VEGFA, ARMS2/HTRA1, TIMP3, and HSPH1/B3GALTL.
The rare C3 variant, K155Q, conferred borderline risk (P =
0.06). A lower risk of progression was seen for the protec-
tive variant in the gene C2, but ABCA1 was no longer signif-
icant (P = 0.07), although the effect size was similar in both
models (HR, 0.68–0.73). The other genetic variants were not
associated with the progression in drusen size. The magni-
tude of the effects for the risk genotypes ranged from an
increased risk of progression of drusen size of 27% for
ARMS2/HTRA1 (HR, 1.27), to more than a four-fold higher
risk of drusen size progression for the rare CFH R1210C vari-
ant (HR, 4.26). C2 was associated with a reduction in risk of
57% (HR, 0.43).
Table 2 displays the stepwise model of genetic factors
related to drusen size progression. HRs represent risk
per allele. After applying the stepwise selection crite-
ria, 11 genetic variants in 8 genes were selected for
inclusion in the model. These include CFH rs1061170
(Y402H), CFH rs1410996, CFH rs121913059 (R1210C), C2
rs9332739 (E318D), C3 rs2230199 (R102G), C3 K115Q,
VEGFA, ARMS2/HTRA1 rs10490924, TIMP3 rs9621532,
NPLOC4/TSPAN10, and HSPH1/B3GALTL rs9542236. HRs
ranged from 1.16 to 5.85 for the risk variants, and the HR was
0.44 for the protective variant. These genetic variants, inde-
pendently associated with drusen size progression, are in the
complement, angiogenesis, immune, inflammatory, extracel-
lular matrix, and DNA repair/protein binding pathways.
Table 3 displays the associations between drusen size
progression, genetic susceptibility, and aMeDi score after
adjustment for baseline demographic, behavioral, and ocular
characteristics, as well as both genetic susceptibility and
aMeDi diet in the same model. Genetic susceptibility and
adherence to aMeDi diet were independently associated
with drusen progression. Although smoking tended to be
associated with drusen growth when adjusted only for age
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TABLE 1. Associations Between Drusen Size Progression and Genetic Susceptibility
Progressors Nonprogressors Model 1* Model 2†
n (%) n (%) HR (95% CI) P Value‡ HR (95% CI) P Value‡
587 (19.4) 2436 (80.6)
Complement pathway
CFH Y402H: rs1061170 <0.001 0.11
TT 179 (30.5) 949 (39.0) Ref
CT 268 (45.7) 1098 (45.0) 1.28 (1.04–1.58) 1.24 (0.94–1.64)
CC 140 (23.8) 389 (16.0) 1.73 (1.36–2.2) 1.28 (0.9–1.82)
CFH: rs1410996 <0.001 0.02
TT 80 (13.6) 430 (17.7) Ref
CT 229 (39.0) 1148 (47.1) 1.07 (0.81–1.41) 1.01 (0.7–1.46)
CC 278 (47.4) 858 (35.2) 1.64 (1.24–2.16) 1.44 (0.97–2.15)
CFH R1210C: rs121913059 0.25 <0.001
CC 584 (99.5) 2431 (99.8) Ref
TC 3 (0.5) 5 (0.2) 2.37 (0.54–10.37) 4.26 (1.69–10.74)
CFH N1050Y: rs35274867 0.15 0.15
AA 578 (98.5) 2363 (97.0) Ref
TA/TT 9 (1.5) 73 (3.0) 0.59 (0.28–1.22) 0.52 (0.2–1.4)
CFI: rs10033900 0.08 0.19
CC 137 (23.3) 666 (27.3) Ref
CT 305 (52.0) 1186 (48.7) 1.23 (0.99–1.53) 1.23 (0.97–1.57)
TT 145 (24.7) 584 (24.0) 1.25 (0.97–1.62) 1.24 (0.94–1.64)
CFB R32Q: rs641153 0.71 0.64
CC 583 (99.3) 2413 (99.1) Ref
CT/TT 4 (0.7) 23 (0.9) 0.80 (0.24–2.63) 0.80 (0.23–2.75)
C2 E318D: rs9332739 0.001 <0.001
GG 561 (95.6) 2212 (90.8) Ref
CC/CG 26 (4.4) 224 (9.2) 0.48 (0.3–0.75) 0.43 (0.26–0.7)
C3 R102G: rs2230199 <0.001 <0.001
CC 315 (53.7) 1564 (64.2) Ref
CG 219 (37.3) 782 (32.1) 1.30 (1.08–1.57) 1.37 (1.114–1.68)
GG 53 (9.0) 90 (3.7) 2.26 (1.65–3.1) 2.35 (1.67–3.33)
C3 K155Q: rs147859257 0.22 0.06
TT 575 (98.0) 2409 (98.9) Ref
GT 12 (2.0) 27 (1.1) 1.66 (0.74–3.73) 2.08 (0.92–4.68)
C9 P167S: rs34882957 0.64 0.34
GG 576 (98.1) 2399 (98.5) Ref
AG 11 (1.9) 37 (1.5) 1.18 (0.6–2.33) 1.16 (0.56–2.41)
Angiogenesis pathway
VEGFA: rs943080 0.09 0.05
CC 113 (19.3) 589 (24.2) Ref
CT 319 (54.3) 1211 (49.7) 1.29 (1.02–1.64) 1.29 (1.00–1.67)
TT 155 (26.4) 636 (26.1) 1.27 (0.97–1.66) 1.33 (0.98–1.77)
TGFBR1: rs334353 0.54 0.75
TT 332 (56.6) 1403 (57.6) Ref
GT 210 (35.8) 874 (35.9) 0.99 (0.82–1.2) 1.03 (0.83–1.26)
GG 45 (7.6) 159 (6.5) 1.20 (0.85–1.7) 1.02 (0.68–1.53)
Lipid pathway
LIPC: rs10468017 0.57 0.32
CC 308 (52.5) 1259 (51.7) Ref
TC 244 (41.6) 988 (40.6) 0.83 (0.55–1.25) 0.80 (0.52–1.24)
TT 35 (5.9) 189 (7.7) 1.01 (0.84–1.21) 0.96 (0.79–1.17)
CETP: rs3764261 0.26 0.20
CC 244 (41.6) 1087 (44.6) Ref
AC 279 (47.5) 1106 (45.4) 1.10 (0.91–1.33) 1.17 (0.96–1.44)
AA 64 (10.9) 243 (10.0) 1.15 (0.85–1.56) 1.29 (0.93–1.79)
ABCA1: rs1883025 0.02 0.07
CC 354 (60.3) 1315 (54.0) Ref
TC 205 (34.9) 952 (39.1) 0.85 (0.70–1.03) 0.87 (0.71–1.07)
TT 28 (4.8) 169 (6.9) 0.68 (0.44–1.03) 0.73 (0.46–1.13)
APOC1/APOE: rs4420638 0.25 0.98
AA 434 (73.9) 1720 (70.6) Ref
GA 153 (26.1) 716 (29.4) 0.89 (0.72–1.09) 1.01 (0.82–1.26)
APOH: rs1801689 0.99 0.31
AA 547 (93.2) 2278 (93.5) Ref
CA/CC 40 (6.8) 158 (6.5) 1.00 (0.72–1.4) 1.23 (0.86–1.75)
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TABLE 1. Continued
Progressors Nonprogressors Model 1* Model 2†
n (%) n (%) HR (95% CI) P Value‡ HR (95% CI) P Value‡
Immune inflammatory pathway
ARMS2/HTRA1 A69S: rs10490924 <0.001 <0.001
GG 294 (50.1) 1497 (61.5) Ref
GT 251 (42.7) 803 (33.0) 1.53 (1.27–1.84) 1.61 (1.31–1.97)
TT 42 (7.2) 136 (5.5) 1.40 (0.98–2.01) 1.27 (0.87–1.85)
PELI3 A307V:rs145732233 0.83 0.82
CC 583 (99.3) 2414 (99.1) Ref
TC 4 (0.7) 22 (0.9) 0.87 (0.23–3.29) 0.86 (0.23–3.26)
TNFRSF10A: rs13278062 0.46 0.57
TT 149 (25.4) 640 (26.3) Ref
GT 294 (50.1) 1247 (51.2) 1.03 (0.82–1.28) 1.05 (0.83–1.35)
GG 143 (24.5) 549 (22.5) 1.10 (0.86–1.42) 1.08 (0.82–1.43)
SLC16A8: rs8135665 0.48 0.83
CC 385 (65.6) 1575 (64.7) Ref
TC 182 (31.1) 774 (31.8) 0.95 (0.78–1.16) 1.03 (0.84–1.27)
TT 20 (3.3) 87 (3.5) 0.86 (0.50–1.46) 0.78 (0.42–1.43)
PILRB/PILRA: rs11769700 0.21 0.23
TT 359 (61.2) 1544 (63.4) Ref
CT 207 (35.3) 795 (32.6) 1.16 (0.96–1.41) 1.15 (0.93–1.42)
CC 21 (3.5) 97 (4.0) 1.04 (0.62–1.77) 1.06 (0.57–1.94)
TMEM97/VTN: rs704 0.55 0.82
AA 143 (24.4) 588 (24.1) Ref
AG 296 (50.4) 1155 (47.4) 1.14 (0.91–1.42) 1.20 (0.94–1.53)
GG 148 (25.2) 693 (28.5) 0.93 (0.72–1.2) 0.98 (0.74–1.3)
Extracellular matrix
COL8A1 P195L: rs13095226 0.56 0.69
TT 488 (83.1) 1985 (81.5) Ref
CT/CC 99 (16.9) 451 (18.5) 0.93 (0.74–1.18) 0.95 (0.73–1.24)
COL4A3: rs11884770 0.67 0.90
CC 300 (51.1) 1291 (53.0) Ref
TC 245 (41.7) 935 (38.4) 0.93 (0.65–1.31) 0.84 (0.55–1.29)
TT 42 (7.2) 210 (8.6) 1.12 (0.93–1.35) 1.16 (0.95–1.43)
CTRB1: rs8056814 0.37 0.29
GG 482 (82.1) 1944 (79.8) Ref
AA/AG 105 (17.9) 492 (20.2) 0.90 (0.72–1.13) 0.88 (0.68–1.13)
ADAMTS9/ADAMTS9-AS2: rs6795735 0.77 0.88
CC 172 (29.3) 727 (29.8) Ref
TC 297 (50.6) 1163 (47.7) 1.09 (0.89–1.35) 1.12 (0.89–1.39)
TT 118 (20.1) 546 (22.5) 0.94 (0.73–1.23) 0.97 (0.72–1.3)
TIMP3: rs9621532 0.06 0.01
AA 516 (87.9) 2200 (90.3) Ref
CA/CC 71 (12.1) 236 (9.7) 1.29 (0.99–1.69) 1.41 (1.05–1.88)
DNA repair/protein binding
RAD51B: rs8017304 0.44 0.85
AA 240 (40.9) 972 (39.9) Ref
AG 272 (46.3) 1101 (45.2) 0.87 (0.65–1.16) 0.90 (0.66–1.24)
GG 75 (12.8) 363 (14.9) 1.01 (0.83–1.22) 1.07 (0.87–1.32)
NPLOC4/TSPAN10: rs9895741 0.19 0.09
GG 240 (40.9) 1067 (43.8) Ref
AG 259 (44.1) 1037 (42.6) 1.08 (0.89–1.32) 1.17 (0.94–1.45)
AA 88 (15.0) 332 (13.6) 1.18 (0.91–1.54) 1.22 (0.91–1.64)
HSPH1/B3GALTL: rs9542236 0.02 0.02
TT 177 (30.1) 811 (33.3) Ref
CT 287 (48.9) 1226 (50.3) 1.09 (0.89–1.34) 1.09 (0.87–1.36)
CC 123 (21.0) 399 (16.4) 1.39 (1.08–1.79) 1.40 (1.06–1.86)
* Model 1: HRs calculated using the Cox proportional hazards model adjusting for age, sex, education, smoking, BMI, drusen size grade
at baseline, AREDS treatment and multivitamin supplement use. Each gene was analyzed separately. Eyes were used as the unit of analysis.
† Model 2: HRs calculated using the Cox proportional hazards model adjusting for age, sex, education, smoking, BMI, drusen size grade
at baseline, AREDS treatment, multivitamin supplement use, and all genetic variants. Eyes were used as the unit of analysis.
‡ P for trend
n (%) refers to the number of eyes.
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TABLE 2. Stepwise Model of Genetic Factors Associated with
Drusen Size Progression
Drusen Size Progression
HR (95% CI)* P Value
Complement pathway
CFH Y402H: rs1061170 1.22 (1.02–1.43) 0.03
CFH: rs1410996 1.22 (1.01–1.48) 0.04
CFH R1210C: rs121913059 5.85 (2.44–14.06) <0.001
C2 E318D: rs9332739 0.44 (0.28–0.69) <0.001
C3 R102G: rs2230199 1.45 (1.26–1.67) <0.001
C3 K155Q: rs147859257 2.19 (0.98–4.88) 0.05
Angiogenesis pathway
VEGFA: rs943080 1.19 (1.04–1.36) 0.01
Immune inflammatory pathway
ARMS2/HTRA1 A69S: rs10490924 1.34 (1.17–1.54) <0.001
Extracellular matrix
TIMP3: rs9621532 1.52 (1.16–2.01) 0.003
DNA repair/protein binding
NPLOC4/TSPAN10: rs9895741 1.16 (1.02–1.32) 0.02
HSPH1/B3GALTL: rs9542236 1.21 (1.06–1.39) 0.005
* HRs for drusen size progression represent risk per allele, and
are adjusted for age, sex, education, smoking, BMI, drusen size
grade at baseline, AREDS treatment, multivitamin supplement use.
Eyes were used as the unit of analysis.
and sex, it was not significantly related in this multivari-
ate model. The calculated genetic risk score ranged from
–0.60 to 2.54. We rounded off the estimates and plotted
their distribution for eyes that progressed and those that did
not progress (Fig. 2). Eyes that progressed to larger drusen
size tended to have higher genetic risk scores and nonpro-
gressors tended to have lower genetic risk scores, although
there was overlap. Eyes of participants with a higher genetic
risk score had about a 2.7-fold increased risk per 1-unit
increase in the score (HR, 2.68; 95% CI, 2.23–3.23; P <
0.001). Figure 3 shows the Kaplan-Meier curves for the prob-
ability of drusen progression depending on the category of
the genetic risk score. For eyes of participants with a genetic
risk score of less than the median, the probability of progres-
sion was 6% at 5 years and 12% at 10 years. For eyes of
participants in the median or higher genetic risk score, the
rates were higher: the 5-year rate of progression was 12%
and the 10-year rate was 26%. A medium/high adherence
to the aMeDi score with four or more components above
the median tended to lower risk for drusen progression
(HR for medium/high adherence 0.83; 95% CI, 0.68–0.99;
P = 0.049). No significant interaction between genetic risk
score and aMeDi score was detected.
DISCUSSION
Drusen are the major clinical signs of early AMD. Although
the association between progression to advanced AMD and
genetic variants is well-established, little is known about the
impact of genetics and diet on drusen size progression. This
study adds new information about earlier stages of AMD
by assessing the influence of genes and a healthy diet on
two-step drusen size progression over 13 years in a large
cohort, controlling for demographic, behavioral, and ocular
factors. When adjusting for all covariates and selecting the
most highly associated genetic variants, risk alleles in seven
genes increased the rate of drusen progression, and protec-
tive alleles in one gene significantly decreased the risk of
drusen progression. Participants with a higher polygenic risk
score were more likely to progress to a larger drusen size.
Our study also highlights for the first time that higher adher-
ence to the Mediterranean diet score (aMeDi score) was
associated with a decreased risk of drusen size progression
adjusting for genetic and other variables. Genetic suscep-
tibility and adherence to aMeDi score were independently
associated with drusen progression.
A previous analysis showed an association between genes
and transition among consecutive stages of AMD based on
the Clinical Age-Related Maculopathy Grading System with
a scale of 1 to 5 from no AMD to advanced stages.6,19 The
incidence of medium drusen among persons without any
AMD at baseline was associated with CFH rs1061170 and
ARMS2.20 A longitudinal analysis of a small subgroup of the
AREDS sample (N = 75) did not find an association between
a genetic score, including 19 common risk variants, and
progression of drusen based on color photos assessed with
an automated algorithm, possibly owing to low power.29 We
have previously shown that carriers of the rare variant CFH
R1210C have a higher drusen burden in the macular and
extra-macular locations,26,30 but no previous studies have
explored the impact of this high impact genetic variant or
the high-risk rare C3 variant31 on drusen size progression.
Both of these rare variants were shown to be associated with
drusen growth in this prospective study.
Our study reports new findings and expands on previous
results in several ways. We explored prospective associ-
ations of drusen size progression determined by a 2-unit
increase in measured drusen size on an ordinal scale. We
analyzed genetic variants including both common and rare
variants, together with a healthy dietary pattern over 13
years. We evaluated a large cohort with a large number of
drusen size progressors. These results highlight the role of
genetics in the transition to larger drusen for both common
and rare variants in various pathways: the complement
pathway–CFH R1210C, C3 K155Q, and C2, and genetic
variants in the angiogenesis, immune, and inflammatory
pathway; extracellular matrix; and DNA repair pathways.
Furthermore, we created a genetic risk score incorporat-
ing the most highly related variants after adjusting for
other covariates, and demonstrated that participants with
a higher polygenic risk score were at higher risk to have
a two-step increase in drusen size, independent of other
factors.
Our results support the impact of the complement path-
way in the development of drusen. Dysregulation owing
to genetic variants leading to uncontrolled activation of
the alternative complement pathway could have an impact
at the level of Bruch’s membrane, and could lead to an
impaired ability to dampen immune complex deposition.
Factor H protein has been found as a molecular constituent
of drusen.32,33 Results are consistent with our previous cross-
sectional study in a different population, which showed that
common variants in CFH are related to higher drusen area
and volume based on automatic OCT measurements.34 The
high-impact, rare CFH R1210C mutation compromises C-
terminal factor H function, and this variant has been shown
to be associated with a high drusen burden and earlier age
of onset of AMD.26,30 Although rare, the CFH R1210C muta-
tion was most highly associated with enlargement of drusen
in these analyses, with almost a six-fold increase in the risk
for drusen growth.
The common C3 R102G single nucleotide polymorphism
influenced drusen growth and is reported to have functional
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TABLE 3. Association Between Drusen Size Progression, Genetic Susceptibility, and aMeDi Score
Progressors Nonprogressors
Mean (SD) Mean (SD) HR (95% CI)* P Value
Genetic Risk score† 1.06 (0.49) 0.81 (0.45) 2.68 (2.23–3.23) <0.001
aMeDi Score n (%) n (%)
Low (0–3) 212 (21) 796 (79) Ref
Medium–high (4–9) 375 (19) 1640 (81) 0.83 (0.68–0.99) 0.049
* HRs calculated using Cox proportional hazards model adjusting for all covariates: age, sex, education, smoking, BMI, drusen size grade
at baseline, total energy intake, AREDS treatment, multivitamin supplement use, genetic risk score (continuous), aMeDi score. For genetic
score, HR is the change for a 1-unit increase. Eyes were used as the unit of analysis.
† Gene score includes: 11 variants in 8 genes: CFH Y402H, CFH rs1410996, CFH R1210C, C2, C3 R102G, C3 K155Q, ARMS2/HTRA1 A69S,
TIMP3, NPLOC4/TSPAN10, VEGFA and HSPH1/B3GALTL. Genetic risk score used as a continuous variable is based on the stepwise model
presented in Table 2.
n (%) refers to the number of eyes.
FIGURE 2. Percent of eyes with drusen progression (2 steps) or no drusen progression during the follow-up time, according to the Genetic
Risk Score.
consequences on the C3 protein. This variant generates
the fast and slow electrophoretic haplotypes of C3 (C3F
and C3S) showing a differential capacity to bind mono-
cyte complement receptor C3F, which is the risk variant for
AMD, and has been previously reported as associated with
other autoimmune-mediated conditions.35–37 Drusen contain
C3 and its activation products membrane attack complex.
The higher impact rare C3 mutation, K155Q, results in resis-
tance to proteolytic inactivation by CFH and CFI, implicat-
ing loss of C3 protein regulation and excessive alternative
complement activation in AMD pathogenesis.31 This vari-
ant also tended to be associated with drusen enlargement.
Evidence suggests that local inflammation and activation of
the complement cascade contribute to the pathogenesis of
drusen and AMD.
The classical pathway of the complement system may
be implicated in drusen progression, because the protec-
tive allele for the C2 R102G variant was associated with a
decreased risk of drusen progression. This variant is also
known to be associated with a decreased risk of advanced
AMD.27,38
Other than CFH and C3, the other genetic variant most
significantly associated with drusen growth is the common
variant in the gene locus ARMS2/HTRA1. In contrast with the
complement pathway, the gene products of ARMS2/HTRA1
and their functional properties as well as the role of this gene
locus in development of drusen and drusen size progres-
sion are less well-understood. These two genes at the chro-
mosome 10q26 locus are in high linkage disequilibrium,
which means that their association is higher than would
be expected if unlinked or associated randomly, and it is
not yet certain which gene product leads to AMD pathol-
ogy. However, it is clear that this biologic pathway plays a
role in nonadvanced stages of AMD, as shown in the current
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FIGURE 3. Kaplan-Meier curves for the probability of eyes progressing to larger drusen size (2 steps) by follow-up time according to high
or low Genetic Risk Score. The survival estimates were obtained from the Kaplan-Meier survival curves.
study of progression in drusen size, and previous studies
with different study designs.19 Furthermore, the variant in
ARMS2/HTRA1 was recently shown to be independently
associated with drusen area and volume measured on OCT,
as was CFH.34 Several studies have proposed that the loss of
ARMS2 protein owing to this mutation may implicate mito-
chondrial dysfunction, which in turn may increase oxidative
stress in the RPE layer.39,40 A study in 2017 found that ARMS2
was expressed in human monocytes and microglia cells and
facilitated removal of cellular debris by local complement
activation; the A69S variant resulted in ARMS2 deficiency,
which could impair the removal of cellular debris at Bruch’s
membrane, possibly leading to the development of drusen.41
However, another study in 2017 presented support for the
gene HTRA1 as the risk factor for AMD, based on protein
expression in eye tissues.42
The VEGFA gene, which relates to the function of angio-
genesis, cell growth, and vascular permeability, is associ-
ated with advanced AMD.43 However, the mode of action of
VEGFA on drusen progression has not yet been explored.
TIMP3 is a tissue inhibitor of metalloproteinases-3, an
extracellular matrix protein. A mutation in this gene has
been shown to disrupt the RPE membrane44 and in a
study on induced pluripotent stem cell-derived RPE, a
TIMP3 mutation was associated with deposits in the RPE
membrane.45 Potential roles in drusen development for
the genes in the DNA repair/protein-binding pathways,
NPLOC4/TSPAN10 and HSPH1/B3GALTL, have not yet been
explored.
In a previous report,46 the ABCA1 gene in the lipoprotein
pathway was implicated in early AMD. ABCA1 protein has
been shown to be expressed in the retina and RPE,47 and
has also been synthetized and expressed in macrophages,
which are the predominant cells involved in creating the
progressive plaque lesions of atherosclerosis.48,49 It is possi-
ble that functional variants regulating the expression level of
ABCA1 promote cholesterol efflux, decrease the activation of
the inflammatory pathway in subretinal drusen, and result
in less drusen accumulation. However, although the ABCA1
variant was associated with drusen progression individually,
it was not retained in the stepwise model as a major factor
in these analyses.
Although individual genetic variants and the genetic
risk score were more significantly associated with drusen
progression in these analyses, diet quality also tended
to modify risk. The protective effects of eating a
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Mediterranean-type diet have been shown for differ-
ent outcomes, such as overall mortality,50 cardiovascular
events,51,52 cognitive decline,53 and more recently vision
impairment, diabetic retinopathy,54 and AMD.13,14,55,56 Two
of the AMD reports are prospective studies showing that
this type of diet decreased the rate of progression from
nonadvanced to advanced AMD—one in the US population
reported in 201513 and the other confirming these results in
a European cohort published in 2019.14 The biological basis
of this healthy diet is based on the protective effects of a diet
rich in nutrient-rich foods: fish providing polyunsaturated
omega-3 fatty acids, and plant foods such as fruits, vegeta-
bles, legumes, olive oil, as well as nuts, providing antioxidant
and anti-inflammatory vitamins and minerals such as vitamin
B9, vitamin E, zinc, lutein, and zeaxanthin.7,11,12,57–59 Our
previous study showed that higher levels of serum antiox-
idants, including vitamin C, lutein, and zeaxanthin, as well
as higher fish intake were associated with lower levels of
C-reactive protein, a marker for systemic inflammation.59
The dietary questionnaire was validated through
a telephone-administrated 24-hour dietary recall on a
subsample, as in other analyses of food frequency question-
naires. The same instrument was used for all individuals,
providing rankings of dietary intake that are useful in
association analyses. We used a well-known and validated
method to assess diet and created a dietary pattern score.
Our aMeDi score was developed by using sex-specific
thresholds to better account for differences between men
and women. Other strengths include standardized data
collection, a long follow-up time, a large number of drusen
size progressors, and data available for major dietary, and
other behavioral confounders. Our analyses accounted for
time to progression in each eye and included genetic vari-
ants in all pathways related to AMD. Dietary assessment was
conducted before drusen progression, which decreased the
likelihood of reverse causation and minimized the potential
for dietary changes as a result of worsening disease. The
phenotypic grading of drusen size was assigned without
knowledge of risk factors or genotype. Our findings are
applicable to an older Caucasian population in the US and
may be relevant for similar populations in other countries.
In conclusion, this study presents new information which
shows that genetic variants and a genetic risk score involving
several biologic pathways significantly influenced a two-step
increase in drusen growth, and that higher adherence to a
Mediterranean-type diet may be associated with a reduced
risk of drusen size progression over time. Modifiable factors
such as a healthy dietary pattern could play a role in delay-
ing progression of earlier stages of AMD, in addition to the
known role of these healthy behaviors on progression to
more advanced disease. Genetic predictors and diet qual-
ity were independently related to an increase in drusen size.
Knowledge of nature and nurture, genetic susceptibility, and
modifiable factors, may identify participants at a greater risk
of early disease progression who could benefit from preven-
tive measures.7
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